Results 331 to 340 of about 152,178 (350)

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Cancer Cell, 2009
Teemu T Junttila, Gail D Lewis Phillips
exaly  

Trastuzumab

Reactions Weekly, 2010
openaire   +1 more source

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2012
José Baselga, Serena Di Cosimo, Evandro de Azambuja   +2 more
exaly  

Trastuzumab/trastuzumab-deruxtecan

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2017
  +4 more sources

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Lancet Oncology, The, 2016
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino   +2 more
exaly  

Trastuzumab/trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly
  +4 more sources

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

The Lancet Oncology, 2019
K. Tamura, J. Tsurutani, S. Takahashi, H. Iwata, I. Krop, C. Redfern, Y. Sagara, T. Doi, Haeseong Park, R. Murthy, R. Redman, Takahiro Jikoh, Caleb Lee, M. Sugihara, J. Shahidi, A. Yver, S. Modi   +16 more
semanticscholar   +1 more source

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Lancet, The, 2010
Luca Gianni, Vladimir Semiglazov, Alexey Manikhas   +2 more
exaly